[Black Down-Pointing Triangle] Daclizumab for MS

    loading  Checking for direct PDF access through Ovid

Abstract

[Black Down-Pointing Triangle]Daclizumab (Zinbryta—Biogen Idec) is a new injectable disease-modifying drug licensed for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 It is a humanised monoclonal antibody that modulates interleukin-2 signalling.1-3 Here, we review the evidence on daclizumab and consider its place in the management of MS.

Related Topics

    loading  Loading Related Articles